4-[(1,6-diethyl-5-{[(2-furanylcarbonyl)amino]methyl}-1H-pyrazolo[3,4-b]pyridin-4-yl)amino]-1-piperidinecarboxamide

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡唑并吡啶类
• 英文名称: 4-[(1,6-diethyl-5-{[(2-furanylcarbonyl)amino]methyl}-1H-pyrazolo[3,4-b]pyridin-4-yl)amino]-1-piperidinecarboxamide
• 英文别名: 4-[[1,6-Diethyl-5-[(furan-2-carbonylamino)methyl]pyrazolo[3,4-b]pyridin-4-yl]amino]piperidine-1-carboxamide
• 化学式: C₂₂H₂₉N₇O₃
• 分子量: 439.517
• InChiKey: JGWNHSQWYWQVPM-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  32
• 可旋转键数：
  7
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.45
• 拓扑面积：
  131
• 氢给体数：
  3
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  糠酸（呋喃甲酸） 、 4-{[5-(aminomethyl)-1,6-diethyl-1H-pyrazolo[3,4-b]pyridin-4-yl]amino}-1-piperidinecarboxamide 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 N,N-二异丙基乙胺 作用下， 以 N,N-二甲基甲酰胺 为溶剂， 反应 18.0h， 生成 4-[(1,6-diethyl-5-{[(2-furanylcarbonyl)amino]methyl}-1H-pyrazolo[3,4-b]pyridin-4-yl)amino]-1-piperidinecarboxamide
  参考文献：
  名称：

  WO2007/36733

  摘要：

  公开号：

文献信息

• Pyrazolo[3,4-b]pyridine compounds, and their use as a PDE4 inhibitors
  申请人：Edlin Christopher David

  公开号：US20090131431A1

  公开（公告）日：2009-05-21

  The invention provides a compound of formula (I) or a salt thereof: wherein R 2 is H, C 1-3 alkyl, n-butyl, C 1-2 fluoroalkyl, cyclopropyl, cyclobutyl, (cyclopropyl)methyl-, —CN, or —CH 2 OH; R 3 is inter alia optionally substituted C 4-7 cycloalkyl or an optionally substituted heterocyclic group (aa), (bb) or (cc); R a is H, methyl or ethyl; R b is H or methyl; R 4 is H, methyl, ethyl, n-propyl, —C(O)-Me, or —C(O)—C 1 fluoroalkyl; and R 5 is: —C(O)—(CH 2 ) n —Ar, —C(O)-Het, —C(O)—C 1-6 alkyl, —C(O)—C 1 fluoroalkyl, —C(O)—(CH 2 ) 2 —C(O)—NR 15b NR 15b , —C(O)—CH 2 —C(O)—NR 15b NR 15b , —C(O)—NR 15b —(CH 2 )m 1 —Ar, —C(O)—NR 15b —Het, —C(O)—NR 15b —C 1-6 alkyl, —C(O)—NR 5a R 5b , —S(O) 2 —(CH 2 ) m 2 —Ar, —S(O) 2 -Het, —S(O) 2 —C 1-6 alkyl, or —CH 2 —Ar; or R 4 and R 5 taken together are —(CH 2 ) p 1 —, —(CH 2 ) 2 —X 5 —(CH 2 ) 2 —, —C(O)—(CH 2 ) p 2 —, —C(O)—N(R 15 )—(CH 2 ) p 3 —; or NR 4 R 5 is of sub-formula (y), (y1), (y2) or (y3). The invention provides the use of the compounds as inhibitors of phosphodiesterase type IV (PDE4) and/or for the treatment and/or prophylaxis of inflammatory and/or allergic diseases such as COPD and the like.

  该发明提供了化合物的结构式(I)或其盐：其中R2为H、C1-3烷基、正丁基、C1-2氟烷基、环丙基、环丁基、(环丙基)甲基、—CN或—CH2OH；R3为可选择地取代的C4-7环烷基或可选择地取代的杂环基(aa)、(bb)或(cc)；R为H、甲基或乙基；R为H或甲基；R为H、甲基、乙基、正丙基、—C(O)-甲基或—C(O)—C1氟烷基；以及R为：—C(O)—(CH2)n—Ar、—C(O)-Het、—C(O)—C1-6烷基、—C(O)—C1氟烷基、—C(O)—(CH2)2—C(O)—NR15bNR15b、—C(O)—CH2—C(O)—NR15bNR15b、—C(O)—NR15b—(CH2)m1—Ar、—C(O)—NR15b—Het、—C(O)—NR15b—C1-6烷基、—C(O)—NR5aR5b、—S(O)2—(CH2)m2—Ar、—S(O)2-Het、—S(O)2—C1-6烷基或—CH2—Ar；或R和R5一起为—(CH2)p1—、—(CH2)2—X5—(CH2)2—、—C(O)—(CH2)p2—、—C(O)—N(R15)—(CH2)p3—；或NR4R5为子式(y)、(y1)、(y2)或(y3)。该发明提供了这些化合物作为磷酸二酯酶IV型(PDE4)的抑制剂以及用于治疗和/或预防炎症和/或过敏性疾病，如慢性阻塞性肺病(COPD)等的用途。
• PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS
  申请人：GLAXO GROUP LIMITED

  公开号：EP1940835B1

  公开（公告）日：2011-03-30
• [EN] PYRAZOLO[3,4-B]PYRIDINE COMPOUNDS, AND THEIR USE AS PDE4 INHIBITORS<br/>[FR] COMPOSES DE PYRAZOLO[3,4-B]PYRIDINE ET LEUR UTILISATION COMME INHIBITEURS DE PDE4
  申请人：GLAXO GROUP LTD

  公开号：WO2007036733A1

  公开（公告）日：2007-04-05

  [EN] The invention provides a compound of formula (I) or a salt thereof: wherein R² is H, C_1-3alkyl, n butyl, C1-2fluoroalkyl, cyclopropyl, cyclobutyl, (cyclopropyl)methyl , CN, or CH₂OH; R³ is inter alia optionally substituted C_4-7cycloalkyl or an optionally substituted heterocyclic group (aa), (bb) or (cc); R^a is H, methyl or ethyl; R^b is H or methyl; R⁴ is H, methyl, ethyl, n propyl, C(O) Me, or C(O) C1fluoroalkyl; and R⁵ is: C(O) (CH2)_n Ar, C(O) Het, C(O) C₁ 6alkyl, C(O) C1fluoroalkyl, C(O) (CH₂)₂ C(O) NR^15bNR^15b, C(O) CH₂ C(O) NR^15bNR¹⁵b, C(O) NR^15b (CH2)m¹ Ar, C(O) NR^15b Het, C(O) NR^15b C_1-6 alkyl, C(O) NR^5aR^5b, S(O)₂ (CH₂)m²-^Ar, S(O)₂ Het, S(O)₂-C₁-₆alkyl, or CH₂ Ar; or R⁴ and R⁵ taken together are -(CH₂)_p
  [FR] L'invention concerne un composé représenté par la formule (I) ou un sel de ce composé. Dans cette formule, R² est H, C_1-3alkyle, n butyle, C1-2fluoroalkyle, cyclopropyle, cyclobutyle, (cyclopropyl)méthyle, CN, ou CH₂OH; R³ est entre autres un C_4-7cycloalkyle éventuellement substitué ou un groupe hétérocyclique (aa), (bb) ou (cc) éventuellement substitué; R^a est H, méthyle or éthyle; R^b est H ou méthyle; R⁴ est H, méthyle, éthyle, n propyle, C(O) Me, ou C(O) C1fluoroalkyle; et R⁵ est: C(O) (CH2)_n Ar, C(O) Het, C(O) C₁ 6alkyle, C(O) C1fluoroalkyle, C(O) (CH₂)₂ C(O) NR^15bNR^15b, C(O) CH₂ C(O) NR^15bNR¹⁵b, C(O) NR^15b (CH2)m¹ Ar, C(O) NR^15b Het, C(O) NR^15b C_1-6 alkyle, C(O) NR^5aR^5b, S(O)₂ (CH₂)m²-^Ar, S(O)₂ Het, S(O)₂-C₁-₆alkyle, ou CH₂ Ar; ou R⁴ et R⁵ pris ensemble sont -(CH₂)_p
• WO2007/36733
  申请人：——

  公开号：——

  公开（公告）日：——